Ergebnisse des Dosis-Eskalationsteils der klinischen Phase-1-Studie mit ISB 2001 bei Patienten mit stark vorbehandeltem multiplem Myelom werden auf der ASCO-Jahrestagung 2025 vorgestellt NEW YORK, 6. Mai 2025 /PRNewswire/ -- IGI, ein globales, voll integriertes Biotechnologieunternehmen...
Hence then, the article about ichnos glenmark innovation igi erhalt fda fast track zulassung fur isb 2001 zur behandlung des rezidivierten refraktaren multiplen myeloms was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Ichnos Glenmark Innovation (IGI) erhält FDA-Fast-Track-Zulassung für ISB 2001 zur Behandlung des rezidivierten/refraktären multiplen Myeloms )
Also on site :
- Natural gas line rupture stops traffic on 5 Freeway in Castaic
- 30–35 terrorists on radar: Army steps up counterterror ops in J&K; intense vigil amid 'Chillai Kalan'
- No. 20 Virginia notches first 11-win season by beating 25th-ranked Missouri in the Gator Bowl